Editas Medicine and Genevant Sciences will collaborate to ... was one concerning Casgevy (exagamglogene autotemcel), the ...

Editas Medicine is pushing its in vivo gene therapy strategy to the top of its agenda, boasting proof-of-concept data and ...

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...

Editas, one of the oldest CRISPR-focused biotechs, is pivoting again — to a sickle cell treatment that requires editing a ...

Shares of Editas Medicine EDIT plunged 12.5% on Tuesday after announcing that it is seeking a global partner to advance its ...

Editas signs a license agreement with Genevant Sciences to develop novel mRNA-LNP gene editing therapeutics. Shares rise in after-hours trading.

Achieved in vivo preclinical proof of concept of hematopoietic stem and progenitor cell editing by utilizing Editas Medicine’s proprietary ...

Editas Medicine, Inc. ( NASDAQ: EDIT) Strategic Update Conference Call October 22, 2024 8:00 AM ET ...

Editas Medicine, Inc. struck a deal on October 3 ... Better, the U.S. FDA has already approved gene therapy treatments for forms of cancer, muscular atrophy, hemophilia and sickle cell anemia. B ...

ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- ., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, ...

The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.

Gene therapy companies, like Editas, carry additional risks due to the therapies being a new class in the field of medicine and its complex regulatory environment. Even if a gene therapy receives ...